Last updated: November 4, 2026
PreHevbrio, VBI Vaccines’ three-antigen hepatitis B vaccine for adults, entered the U.S. market in 2021 but failed to achieve commercial scale. Its addressable market expanded after the CDC recommended universal hepatitis B vaccination for adults ages 19 through 59, yet the product faced entrenched competition from Engerix-B, Recombivax HB, and Heplisav-B. VBI later withdrew PreHevbrio from the U.S. market amid manufacturing and commercial constraints. The withdrawal eliminated near-term U.S. revenue potential and left the product with limited strategic value outside a potential licensing or asset-sale transaction.
What is PreHevbrio and how does it compete in the hepatitis B vaccine market?
PreHevbrio is a recombinant hepatitis B vaccine containing three hepatitis B surface antigens derived from different viral subtypes. The FDA approved it on November 30, 2021, for prevention of infection caused by all known subtypes of hepatitis B virus in adults ages 18 and older. The vaccine is administered as a three-dose series at zero, one, and six months. [1]
The principal commercial competitors are:
| Product |
Company |
Adult dosing |
Competitive position |
| PreHevbrio |
VBI Vaccines |
Three doses over six months |
Three-antigen formulation; U.S. withdrawal curtailed availability |
| Engerix-B |
GSK |
Three doses over six months |
Established global brand and public-sector presence |
| Recombivax HB |
Merck |
Three doses over six months |
Established U.S. vaccine with broad institutional use |
| Heplisav-B |
Dynavax |
Two doses over one month |
Faster schedule and strong adult-market differentiation |
| Twinrix |
GSK |
Three-dose or accelerated schedules |
Combined hepatitis A and B protection |
PreHevbrio’s technical differentiation was its three-antigen composition. Its principal commercial weakness was the lack of a shorter dosing schedule. Heplisav-B can complete adult immunization in one month, while PreHevbrio required six months under its standard schedule. That difference matters in occupational health, travel medicine, diabetes clinics, pharmacies, and other settings where completion rates affect product selection.
How large was the market opportunity for PreHevbrio?
The U.S. adult hepatitis B market expanded after the CDC issued its 2022 recommendation for universal vaccination of adults ages 19 through 59. Adults age 60 and older became eligible based on risk factors or individual request. [2]
The recommendation increased the potential number of vaccine candidates beyond the historic risk-based market. Major demand segments include:
- Adults with diabetes
- Health-care and public-safety workers
- People with multiple sex partners
- People who inject drugs
- Household or sexual contacts of infected individuals
- Patients receiving hemodialysis
- People experiencing homelessness
- International travelers
- Adults seeking vaccination through pharmacies and primary care
The market expansion favored products that could secure pharmacy access, employer contracts, government procurement, and health-system formulary placement. PreHevbrio entered after the policy expansion was announced, but VBI lacked the commercial infrastructure of GSK, Merck, and Dynavax.
The U.S. opportunity was also shaped by completion behavior. A six-month schedule creates more opportunities for patients to miss a dose. Heplisav-B’s two-dose, one-month schedule gave Dynavax a practical advantage in adult vaccination programs where speed and compliance are priorities.
What was PreHevbrio’s financial trajectory?
PreHevbrio generated only limited product revenue before the U.S. withdrawal. VBI’s public filings reported approximately $2.8 million of product revenue in 2022 and approximately $4.5 million in 2023, with PreHevbrio representing the principal commercial product source. [3][4]
| Financial period |
Reported product revenue |
Commercial interpretation |
| 2021 |
Pre-commercial launch period |
FDA approval in November; limited launch contribution |
| 2022 |
Approximately $2.8 million |
Initial launch year with restricted commercial penetration |
| 2023 |
Approximately $4.5 million |
Growth from a low base, but inadequate to support the operating structure |
| 2024 onward |
No meaningful U.S. growth opportunity after withdrawal |
Commercial value impaired by market exit and supply limitations |
The trajectory showed percentage growth but not scale. Revenue increased by roughly 60% from 2022 to 2023, yet absolute sales remained small compared with the cost of clinical development, regulatory compliance, manufacturing, sales infrastructure, and public-company operations.
VBI continued to report substantial operating losses and liquidity pressure during the commercialization period. PreHevbrio’s revenue did not offset the company’s broader cash requirements. The product therefore remained economically dependent on external financing, strategic transactions, or a commercial partner with an established vaccine infrastructure.
When did PreHevbrio lose commercial exclusivity?
PreHevbrio did not lose exclusivity through ordinary generic entry. The primary value destruction came from withdrawal and commercialization failure rather than a confirmed competitive launch based on patent expiry.
The product’s key regulatory dates are:
| Event |
Date |
| FDA approval |
November 30, 2021 |
| U.S. adult hepatitis B universal recommendation |
April 2022 |
| Commercial growth period |
2022-2023 |
| U.S. market withdrawal period |
2024 |
| Post-withdrawal commercial position |
No sustained U.S. market presence |
As a biologic vaccine, PreHevbrio is regulated under a biologics license application rather than a conventional small-molecule new drug application. FDA biologic exclusivity is distinct from Orange Book patent exclusivity. The product received 12 years of reference-product exclusivity under the Biologics Price Competition and Innovation Act framework, subject to the statutory rules governing biosimilar applications. [5]
Regulatory exclusivity did not guarantee commercial success. A reference biologic can retain regulatory exclusivity while losing practical market value because of manufacturing problems, supply interruption, weak contracting, or the withdrawal of the sponsor.
What is the Orange Book and Purple Book status of PreHevbrio?
PreHevbrio is not an Orange Book-listed small-molecule drug. It is a biologic vaccine licensed under a BLA and is evaluated through the Purple Book framework rather than the conventional Orange Book substitution system. [5][6]
This distinction has several commercial consequences:
- There is no standard Abbreviated New Drug Application pathway for an interchangeable generic version.
- A competing biologic would generally require its own BLA or a biosimilar application under section 351(k).
- Vaccine substitution is driven more by procurement, formularies, public-health recommendations, contracting, and supply than by automatic pharmacy substitution.
- Patent information is not presented in the same standardized product-by-product format used for small-molecule products in the Orange Book.
Are there Paragraph IV challenges to PreHevbrio?
No significant public Paragraph IV challenge is associated with PreHevbrio. Paragraph IV litigation is a Hatch-Waxman mechanism for patents listed against small-molecule products. It is not the ordinary legal pathway for challenging a vaccine licensed as a biologic.
A future biosimilar applicant would face the BPCIA patent-exchange process rather than a conventional Paragraph IV certification. The commercial likelihood of such an application is low while the reference product has limited sales and uncertain supply. A biosimilar developer would need to justify the cost of comparative development, manufacturing validation, regulatory submission, and market access against a small commercial base.
What patents protect PreHevbrio?
PreHevbrio’s commercial protection is based on a combination of biologic regulatory exclusivity, manufacturing know-how, antigen-production processes, formulation controls, quality systems, and any applicable composition or method patents. Public market sources do not establish a single, widely recognized patent family that functions as the principal market barrier for PreHevbrio.
The most relevant protection categories are:
Antigen composition and particle design
PreHevbrio uses three hepatitis B surface antigens. Claims covering antigen combinations, subtype selection, antigen presentation, or immunogenic compositions could have technical value, but their commercial effect depends on claim scope and enforceability.
Manufacturing and purification
The manufacturing process can be more important than the product label. Relevant barriers may include recombinant antigen expression, purification, particle assembly, adjuvant integration, in-process controls, and release testing. These processes can be protected by patents and trade secrets.
Formulation and presentation
Product protection may extend to adjuvant systems, antigen ratios, stability conditions, vial or syringe presentation, and storage requirements. Formulation claims have limited value if a competitor can design around them while producing a clinically comparable vaccine.
Method-of-use claims
Method-of-use claims could cover vaccination of adult populations or dosing regimens. Such claims generally provide narrower protection than a composition claim and are difficult to enforce against broad vaccination practices unless infringement is clear.
The absence of a large visible patent litigation record indicates that patent enforcement was not the central commercial issue. Manufacturing continuity and market access were more important.
What caused PreHevbrio’s U.S. withdrawal?
VBI announced the withdrawal of PreHevbrio from the U.S. market in 2024. Public company disclosures connected the decision to manufacturing and commercial constraints, including the difficulty of maintaining a viable supply and operating model for the product. [4][7]
The withdrawal changed the product’s risk profile:
- U.S. prescribers lost a reliable supply option.
- VBI lost access to the largest near-term commercial market.
- The CDC recommendation could no longer translate into meaningful PreHevbrio demand.
- Any remaining value shifted toward overseas licensing, manufacturing rights, technology transfer, or acquisition of related assets.
- The probability of a standalone U.S. relaunch declined sharply without a new capital source or manufacturing partner.
A market withdrawal also creates reputational and contracting disadvantages. Health systems and public purchasers generally prefer products with stable supply, multiple manufacturing contingencies, and established pharmacovigilance operations.
Which companies are challenging PreHevbrio?
No company appears to have challenged PreHevbrio through a high-profile patent case or biosimilar litigation. Competitive pressure came from established vaccine manufacturers and differentiated adult-vaccine products.
Dynavax presented the most direct commercial challenge through Heplisav-B’s two-dose schedule. GSK and Merck had stronger distribution, longer-standing procurement relationships, and established physician familiarity. Their products did not need to displace PreHevbrio through litigation. They competed through availability, contracting, and clinical workflow.
How strong was the PreHevbrio patent estate?
The patent estate was commercially weak relative to the broader market barriers controlled by incumbent vaccine suppliers. Its potential strengths were the complexity of the three-antigen platform and the difficulty of reproducing manufacturing quality. Its weaknesses were the lack of commercial scale, limited evidence of enforcement activity, absence of a dominant Orange Book-style patent position, and the product’s withdrawal from the U.S. market.
| Patent-estate factor |
Assessment |
| Composition differentiation |
Moderate technical differentiation |
| Manufacturing complexity |
Potentially meaningful barrier |
| Regulatory exclusivity |
Strong in duration, limited by withdrawal |
| Orange Book leverage |
Not applicable |
| Paragraph IV exposure |
Not applicable in the conventional sense |
| Biosimilar threat |
Low near term because of limited market value |
| Litigation record |
No major public challenge identified |
| Commercial durability |
Weak after U.S. withdrawal |
What licensing deals or asset transactions could preserve value?
A licensing transaction would need to solve three problems: manufacturing, distribution, and working capital. The most logical counterparties would be vaccine manufacturers with spare capacity, regional public-health distribution, or existing hepatitis B portfolios.
Potential transaction structures include:
- Regional licensing outside the United States
- Transfer of manufacturing rights
- Co-commercialization with an established vaccine company
- Sale of formulation and production technology
- Supply agreement tied to public-sector procurement
- Acquisition of the product rights alongside other VBI assets
The product’s value would likely be greater to a company that can use existing manufacturing and sales infrastructure than to a financial buyer. A standalone acquisition would inherit regulatory obligations, quality-system costs, and supply-chain risk.
What generic or biosimilar launch risks exist?
The immediate risk is not a conventional generic launch. It is substitution by existing vaccines and permanent loss of prescriber confidence.
A future biosimilar or follow-on vaccine would face:
- Limited commercial incentive because PreHevbrio sales were low.
- Need for a viable reference-product and regulatory strategy.
- Manufacturing comparability requirements.
- Procurement competition from established products.
- Possible difficulty obtaining formulary placement after a prior sponsor withdrawal.
- No automatic pharmacy substitution advantage comparable to many small-molecule generics.
The more probable competitive scenario is continued dominance by Engerix-B, Recombivax HB, Heplisav-B, and combination vaccines rather than a new PreHevbrio biosimilar.
How does PreHevbrio compare with Heplisav-B?
| Factor |
PreHevbrio |
Heplisav-B |
| Sponsor |
VBI Vaccines |
Dynavax |
| Antigen approach |
Three hepatitis B surface antigens |
Single-antigen vaccine with CpG 1018 adjuvant |
| Adult schedule |
Three doses over six months |
Two doses over one month |
| FDA approval |
2021 |
2017 |
| Commercial status |
U.S. withdrawal |
Active U.S. commercial presence |
| Main differentiation |
Antigen breadth |
Speed and completion convenience |
| Market result |
Limited uptake |
Stronger adult-market positioning |
Heplisav-B had a clearer operational benefit for adult providers. PreHevbrio’s antigen breadth was scientifically differentiated, but it did not overcome the six-month schedule, limited commercial infrastructure, and manufacturing constraints.
What was the revenue exposure from PreHevbrio?
PreHevbrio represented a small absolute revenue stream but a large strategic share of VBI’s commercial portfolio. The product was effectively the company’s principal marketed asset. That concentration created operating leverage in reverse: every supply or reimbursement problem affected a large portion of the company’s commercial thesis, while the revenue base remained too small to absorb fixed costs.
For investors and potential partners, the main financial conclusions are:
- Revenue growth from 2022 to 2023 was insufficient in absolute terms.
- The product did not reach the scale required to finance VBI independently.
- U.S. withdrawal removed the most important near-term revenue path.
- Patent rights alone could not compensate for manufacturing and distribution weakness.
- Any residual value depended on a partner’s ability to relaunch or commercialize the product at lower incremental cost.
Key Takeaways
- PreHevbrio was FDA-approved in November 2021 for adults ages 18 and older.
- Its three-antigen formulation differentiated it technically, but its six-month dosing schedule limited convenience versus Heplisav-B.
- Reported product revenue rose from approximately $2.8 million in 2022 to approximately $4.5 million in 2023, remaining commercially small.
- The product’s U.S. withdrawal in 2024 was more consequential than ordinary patent expiration.
- PreHevbrio is a biologic vaccine, so Orange Book and Paragraph IV frameworks do not directly apply.
- No major public biosimilar or patent challenge drove the product’s decline.
- The remaining strategic value lies in regional licensing, manufacturing transfer, or acquisition by an established vaccine company.
- The competitive market remains controlled by GSK, Merck, and Dynavax products with stronger supply and distribution positions.
FAQs
Is PreHevbrio still available in the United States?
No. VBI withdrew PreHevbrio from the U.S. market in 2024 amid manufacturing and commercial constraints.
Is PreHevbrio a biosimilar?
No. PreHevbrio is an original recombinant hepatitis B vaccine licensed under a BLA. It is not a biosimilar to Engerix-B, Recombivax HB, or Heplisav-B.
Did PreHevbrio have an Orange Book patent?
No. PreHevbrio is a biologic vaccine, so its regulatory and patent framework does not follow the standard Orange Book model for small-molecule drugs.
Which hepatitis B vaccine has the strongest schedule advantage?
Heplisav-B has the strongest schedule advantage for adults because it uses two doses administered over one month, compared with the traditional six-month three-dose schedule used by PreHevbrio, Engerix-B, and Recombivax HB.
Could PreHevbrio return to the market?
A return would require a new manufacturing and commercialization strategy, regulatory coordination, reliable supply, and sufficient financing. The product’s prior revenue scale indicates that a relaunch would most likely require an established vaccine partner.
References
- U.S. Food and Drug Administration. (2021). PreHevbrio prescribing information.
- Centers for Disease Control and Prevention. (2022). Universal hepatitis B vaccination in adults aged 19-59 years: Updated recommendations of the Advisory Committee on Immunization Practices.
- VBI Vaccines Inc. (2023). Annual report for the fiscal year ended December 31, 2022.
- VBI Vaccines Inc. (2024). Annual report and corporate disclosures for the fiscal year ended December 31, 2023.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- VBI Vaccines Inc. (2024). Corporate announcement regarding the withdrawal of PreHevbrio from the U.S. market.
